Pliant Therapeutics, Inc. (PLRX)
Largest Insider Buys in Sector
PLRX Stock Price History Chart
PLRX Stock Performance
About Pliant Therapeutics, Inc.
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic …
Insider Activity of Pliant Therapeutics, Inc.
Over the last 12 months, insiders at Pliant Therapeutics, Inc. have bought $0 and sold $1.97M worth of Pliant Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Pliant Therapeutics, Inc. have bought $0 and sold $7.6M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
List of Insider Buy and Sell Transactions, Pliant Therapeutics, Inc.
| 2024-07-10 | Sale | President and CEO | 38,710 0.0701% | $11.56 | $447,488 | 0.00% | ||
| 2024-07-10 | Sale | Chief Financial Officer | 10,911 0.0198% | $11.56 | $126,131 | 0.00% | ||
| 2024-07-10 | Sale | Chief Business Officer | 9,900 0.0179% | $11.56 | $114,444 | 0.00% | ||
| 2024-07-10 | Sale | Chief Medical Officer | 12,319 0.0223% | $11.56 | $142,408 | 0.00% | ||
| 2024-07-10 | Sale | General Counsel & Corp. Sec'y | 7,656 0.0139% | $11.56 | $88,503 | 0.00% | ||
| 2024-01-17 | Sale | President and CEO | 25,721 0.0414% | $17.23 | $443,173 | -22.78% | ||
| 2024-01-17 | Sale | Chief Financial Officer | 9,781 0.0157% | $17.23 | $168,527 | -22.78% | ||
| 2024-01-17 | Sale | Chief Business Officer | 9,786 0.0158% | $17.23 | $168,613 | -22.78% | ||
| 2024-01-17 | Sale | Chief Medical Officer | 10,295 0.0166% | $17.23 | $177,383 | -22.78% | ||
| 2024-01-17 | Sale | General Counsel & Corp. Sec'y | 5,197 0.0084% | $17.23 | $89,544 | -22.78% | ||
| 2023-08-04 | Sale | Chief Business Officer | 20,050 0.0337% | $20.01 | $401,201 | -24.96% | ||
| 2023-08-03 | Sale | Chief Business Officer | 14,869 0.0258% | $20.00 | $297,380 | -22.46% | ||
| 2023-07-20 | Sale | General Counsel & Corp. Sec'y | 4,755 0.0085% | $17.55 | $83,450 | -12.11% | ||
| 2023-07-17 | Sale | President and CEO | 70,150 0.1263% | $18.01 | $1.26M | -13.00% | ||
| 2023-07-17 | Sale | Chief Business Officer | 17,937 0.0323% | $18.01 | $323,029 | -13.00% | ||
| 2023-07-17 | Sale | Chief Financial Officer | 19,771 0.0356% | $18.01 | $356,058 | -13.00% | ||
| 2023-07-17 | Sale | Chief Medical Officer | 22,321 0.0402% | $18.01 | $401,981 | -13.00% | ||
| 2023-07-17 | Sale | General Counsel & Corp. Sec'y | 12,778 0.023% | $18.01 | $230,120 | -13.00% | ||
| 2023-04-03 | Sale | General Counsel & Corp. Sec'y | 2,877 0.0052% | $26.79 | $77,066 | -35.48% | ||
| 2023-03-30 | Sale | President and CEO | 35,339 0.063% | $26.52 | $937,222 | -35.31% |
Institutional Investor Ownership
| Deep Track Capital Lp | $85.67M | 9.53 | 5.75M | 0% | +$0 | 0.39 | |
| BlackRock | $69.37M | 7.72 | 4.66M | -3.04% | -$2.18M | <0.01 | |
| T. Rowe Price | $58.99M | 6.56 | 3.96M | +4.57% | +$2.58M | 0.01 | |
| Fidelity Investments | $58.8M | 6.54 | 3.95M | -0.43% | -$252,122.92 | <0.01 | |
| First Light Asset Management | $52.67M | 5.86 | 3.53M | -1.58% | -$846,066.70 | 4.44 |